<DOC>
	<DOCNO>NCT00412373</DOCNO>
	<brief_summary>The purpose study measure effectiveness ass safety different dosage ( 3 mg/day 12 mg/day ) antipsychotic paliperidone extended-release ( ER ) patient experience acute episode schizoaffective disorder .</brief_summary>
	<brief_title>Evaluation Effectiveness Safety Flexible-dose Paliperidone Extended Release Patients With Schizoaffective Disorder .</brief_title>
	<detailed_description>Schizophrenia schizoaffective disorder closely related term symptom , coexist condition , genetic risk . In previous study patient schizophrenia , treatment paliperidone extended-release ( ER ) improve psychotic symptom , well mood symptom evaluate anxiety/depression hostility/excitement Positive Negative Symptoms Schizophrenia ( PANSS ) factor score . Therefore , paliperidone ER may also effective treating symptom schizoaffective disorder . Paliperidone 's limited potential drug-drug interaction particularly important patient population , multiple drug therapy relatively common . This multicenter , double-blind ( neither patient physician know whether drug placebo take , dosage ) , randomize ( patient assign different treatment base chance ) , placebo-controlled , parallel-group study design examine effectiveness safety paliperidone ER adult patient schizoaffective disorder experience acute episode disorder . Patients study randomly assign 1 2 group receive 6 week oral treatment flexible dosage paliperidone ER ( 3-12 mg/day ) placebo . The primary efficacy outcome change baseline Week 6 , last post-randomization assessment double-blind treatment ( endpoint ) , PANSS total score . Safety assess monitor adverse event , clinical laboratory testing , pregnancy testing , vital sign measurement , physical examination , administration 12-lead ECG , movement disorder side effect scale , InterSePT Scale Suicidal Thinking . Patients may also choose participate pharmacogenomic ( DNA ) analysis . The primary study hypothesis flexible-dose paliperidone ER good placebo change baseline PANSS total score acutely ill patient schizoaffective disorder . Patients receive study drug mouth total 43 day . Beginning Day 1 , patient take either placebo paliperidone ER 6 mg/day . After day 4 , dosage may adjust , define interval , dosage 3 mg/day 12 mg/day , inclusive .</detailed_description>
	<mesh_term>Disease</mesh_term>
	<mesh_term>Psychotic Disorders</mesh_term>
	<mesh_term>Mental Disorders</mesh_term>
	<mesh_term>Paliperidone Palmitate</mesh_term>
	<criteria>Diagnostic Statistical Manual Fourth Edition ( DSMIV ) diagnosis schizoaffective disorder A total Positive Negative Symptoms Schizophrenia ( PANSS ) score &gt; = 60 A score &gt; = 16 Young Mania Rating Scale ( YMRS ) score &gt; = 16 Hamilton Depression Rating Scale ( HAMD 21 ) A primary active mental illness diagnosis schizoaffective disorder Patients first episode psychosis Active substance dependence within previous 6 month Treatment clozapine within 6 month randomization A history treatment resistance , defined failure respond 2 adequate trial antipsychotic medication Pregnancy , breastfeeding , plan become pregnant</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>April 2014</verification_date>
	<keyword>Schizoaffective Disorder</keyword>
	<keyword>antipsychotic</keyword>
	<keyword>paliperidone</keyword>
	<keyword>placebo</keyword>
</DOC>